NCT05799690

Brief Summary

The aim of the study is to compare the effects of 2 different dosages and modalities of motor-cognitive rehabilitation in Parkinson's disease with postural instability and gait disorders (PD-PIGD) on clinical features, neuroimaging and blood-based biomarkers at short-term (2 months) and long-term (7 months) follow-up. Fifty subjects with PD-PIGD will be randomized in 2 training groups: DUAL-TASK+AOT-MI and the DUAL-TASK groups. The DUAL-TASK+AOT-MI group will perform a dual-task gait/balance training consisting of action observation training (AOT) and motor imagery (MI) combined with practicing the observed-imagined exercises; DUAL-TASK group will perform the same exercises combined with watching landscape videos. The training will last 6 weeks, 3 times/week, 1 hour per session. Before and after training (W6), all the patients will undergo neurological, gait/balance, cognitive/behavioral, magnetic resonance imaging (MRI) and serum biomarkers evaluations. Neurological, gait/balance, cognitive/behavioral assessments and serum biomarkers will be also repeated at the 14-week follow-up (W14) to assess maintenance of results. Patients of both DUAL-TASK+AOT-MI and DUAL-TASK groups will be further randomized to repeat the training (6 weeks, 3 times/week, 1 hour each session) starting at W14 (DUAL-TASK+AOT-MI\_DOUBLE and DUAL-TASK\_DOUBLE groups). After six weeks (W20) all the subjects repeating the training will be evaluated (neurological, gait/balance, cognitive/behavioral assessments). At 28-week follow-up (W28), the whole sample of patients will be assessed with neurological, gait/balance, cognitive/behavioral, MRI and serum biomarkers evaluations. All MRI scans will be acquired at least 12 hours after last dopaminergic therapy administration to mitigate the pharmacological effects on neural activity. Twenty age- and sex-matched healthy controls will be recruited to perform gait/balance and cognitive/behavioral assessments, blood sample and brain MRI acquisition at baseline. The secondary aims of the study are to define the neuroimaging and blood-based biomarkers of PD-PIGD patients presenting different clinical features (e.g. presence of mild cognitive impairment, freezing of gait, falls and mood disturbances) and to evaluate the role of blood-based and neuroimaging biomarkers, together with clinical characteristics, in predicting the response to different dosages of rehabilitation in PD-PIGD throughout the development of a machine-learning algorithm.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P75+ for not_applicable parkinson-disease

Timeline
12mo left

Started Apr 2023

Longer than P75 for not_applicable parkinson-disease

Geographic Reach
1 country

2 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress76%
Apr 2023Apr 2027

First Submitted

Initial submission to the registry

March 17, 2023

Completed
19 days until next milestone

First Posted

Study publicly available on registry

April 5, 2023

Completed
25 days until next milestone

Study Start

First participant enrolled

April 30, 2023

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 30, 2026

Expected
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 28, 2027

Last Updated

March 9, 2026

Status Verified

May 1, 2025

Enrollment Period

3.3 years

First QC Date

March 17, 2023

Last Update Submit

March 6, 2026

Conditions

Keywords

Parkinson DiseaseGaitRehabilitationBiomarkersMagnetic resonance imaging

Outcome Measures

Primary Outcomes (1)

  • Total execution time of Timed Up and Go test with cognitive dual-task (TUG-COG)

    Changes in time taken to complete the timed up and go test with cognitive dual-task: patients are asked to stand up from a chair, walk for three meters, turn and walk back to the chair while counting backwards by 3 starting from 100. Assessment during ON medication phase.

    Baseline, week 6, week 14 and week 28. At week 20 only for patients repeating the training.

Secondary Outcomes (22)

  • Total execution time of Timed Up and Go test (TUG)

    Baseline, week 6, week 14 and week 28. At week 20 only for patients repeating the training.

  • Total execution time of Timed Up and Go test with manual dual-task (TUG-MAN)

    Baseline, week 6, week 14 and week 28. At week 20 only for patients repeating the training.

  • Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) score

    Baseline, week 6, week 14 and week 28. At week 20 only for patients repeating the training.

  • Brain functional changes during functional magnetic resonance imaging (MRI) tasks

    Baseline, week 6 and week 28

  • Serum concentration of Neurofilament light chain (NfL)

    Baseline, week 6, week 14 and week 28.

  • +17 more secondary outcomes

Study Arms (5)

DUAL-TASK+AOT-MI

EXPERIMENTAL

Dual-task gait and balance training with cognitive facilitations (action observation and motor imagery) for six weeks.

Behavioral: Gait and balance training with dual-task + action observation and motor imagery (six weeks)

DUAL-TASK

ACTIVE COMPARATOR

Dual-task gait and balance training with vision of landscape videos for six weeks.

Behavioral: Gait and balance training with dual-task (six weeks)

DUAL-TASK+AOT-MI_DOUBLE

EXPERIMENTAL

Dual-task gait and balance training with cognitive facilitations (action observation and motor imagery) repeated two times (twelve weeks: 6 + 6).

Behavioral: Gait and balance training with dual-task + action observation and motor imagery (twelve weeks: 6 + 6)

DUAL-TASK_DOUBLE

ACTIVE COMPARATOR

Dual-task gait and balance training with vision of landscape videos repeated two times (twelve weeks: 6 + 6).

Behavioral: Gait and balance training with dual-task (twelve weeks: 6 +6)

Healthy subjects

NO INTERVENTION

Age- and sex-matched healthy subjects recruited to compare gait, neuropsychological, serum and functional magnetic resonance imaging characteristics at baseline.

Interventions

Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing a balance or gait task (action observation - AOT) and will imagine the same exercise (motor-imagery - MI) before task execution. Each training session will be proposed with the following modality: 2 minutes of AOT - 5 minutes of task execution - 2 minutes of MI - 5 minutes of task execution. Patients will be explicitly asked to concentrate on how the actions are performed in the videos and to carefully use MI to improve their motor performance. Patients will not be allowed to perform any movement while watching videos or during MI. 1 hour, 3 times a week for six weeks.

DUAL-TASK+AOT-MI

Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing static landscapes before task execution. Each training session will be proposed with the following modality: 2 minutes of videos - 5 minutes of task execution - 2 minutes of videos - 5 minutes of task execution. 1 hour, 3 times a week for six weeks.

DUAL-TASK

Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing a balance or gait task (action observation - AOT) and will imagine the same exercise (motor-imagery - MI) before task execution. Each training session will be proposed with the following modality: 2 minutes of AOT - 5 minutes of task execution - 2 minutes of MI - 5 minutes of task execution. Patients will be explicitly asked to concentrate on how the actions are performed in the videos and to carefully use MI to improve their motor performance. Patients will not be allowed to perform any movement while watching videos or during MI. The training protocol will be repeated two times: once starting at baseline, once starting after the first follow-up at week 14 (W14) 1 hour, 3 times a week for twelve weeks (6+6).

DUAL-TASK+AOT-MI_DOUBLE

Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing static landscapes before task execution. Each training session will be proposed with the following modality: 2 minutes of videos - 5 minutes of task execution - 2 minutes of videos - 5 minutes of task execution. The training protocol will be repeated two times: once starting at baseline, once starting after the first follow-up at week 14 (W14) 1 hour, 3 times a week for twelve weeks (6+6).

DUAL-TASK_DOUBLE

Eligibility Criteria

Age45 Years - 85 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years ≤ age ≤ 85 years;
  • Idiopathic PD according to the Movement Disorders Society (MDS) diagnostic criteria
  • Hoehn \& Yahr (H\&Y) score \<= 4
  • PIGD phenotype
  • Stable dopaminergic medication for at least 4 weeks and without any changes during the observation period (28 weeks)
  • No dementia according to Litvan's criteria and Mini-Mental Status Examination score (MMSE) \>= 24
  • No significant tremor/involuntary movements that could determine artifacts during the MRI acquisition
  • Oral and written informed consent to study participation
  • sex-matched and age-matched (age range: mean age of PD years ± 15 years);
  • oral and written informed consent to study participation

You may not qualify if:

  • Medical conditions or substance abuse that could interfere with cognition;
  • Any major systemic, psychiatric, neurological, visual, and musculoskeletal disturbances or other causes of walking inability;
  • Contraindications to undergoing MRI examination;
  • Brain damage at routine MRI, including lacunae and extensive cerebrovascular disorders;
  • Denied oral and written informed consent to study participation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

IRCCS San Raffaele

Milan, 20132, Italy

Location

Neurology Unit, Azienda Ospedaliera Universitaria Integrata di Verona

Verona, 37126, Italy

Location

MeSH Terms

Conditions

Parkinson Disease

Interventions

Gait

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Intervention Hierarchy (Ancestors)

Physical ExaminationDiagnostic Techniques and ProceduresDiagnosisWalkingLocomotionMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Physiotherapist, neurologists, neuropsychologists and radiologist assessing the patients are blinded to group allocation.
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: Single-blind randomized controlled trial. Fifty PD patients are randomly divided into two groups: 25 in DUAL-TASK+AOT-MI (experimental) and 25 in the DUAL-TASK (active comparator). Half of the patients are further randomized to repeat the treatment (DUAL-TASK+AOT-MI\_DOUBLE and DUAL-TASK\_DOUBLE). The assessors are blinded to the group allocation. In addition, a group of 20 healthy age- and sex-matched control is included at baseline
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Prof

Study Record Dates

First Submitted

March 17, 2023

First Posted

April 5, 2023

Study Start

April 30, 2023

Primary Completion (Estimated)

July 30, 2026

Study Completion (Estimated)

April 28, 2027

Last Updated

March 9, 2026

Record last verified: 2025-05

Data Sharing

IPD Sharing
Will not share

Locations